Eradication of Helicobacter pylori Infection

Current Gastroenterology Reports

Volumn 18, Issue 7, 2016, Pages

  Marcus, Elizabeth A ^a,b   Sachs, George ^a,b   Scott, David R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Antibiotic resistance; Eradication; Gastric acid; Helicobacter pylori

Indexed keywords

ACETAZOLAMIDE; AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; BISMUTH CITRATE PLUS METRONIDAZOLE PLUS TETRACYCLINE; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE DERIVATIVE; VONOPRAZAN; ANTIINFECTIVE AGENT;

ACID SECRETION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; CHRONIC GASTRITIS; COMBINATION DRUG THERAPY; DISEASE ERADICATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DUODENUM ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MARGINAL ZONE LYMPHOMA; MEDICATION COMPLIANCE; NONHUMAN; POLYPHARMACY; REVIEW; STOMACH ADENOCARCINOMA; STOMACH ULCER; CHRONIC DISEASE; GASTRITIS; HELICOBACTER INFECTIONS; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BISMUTH; CHRONIC DISEASE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS;

EID: 84971505778     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-016-0509-x     Document Type: Review

References (116)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.
2. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992;102(2):720–7.
3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132–6.
4. Parsonnet J. Gastric adenocarcinoma and Helicobacter pylori infection. Western J Med. 1994;161(1):60.
5. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31.
6. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–86.
7. Infection with Helicobacter pylori In: Cancer IAfRo, editor. IARC monographs on the evaluation of the carcinogenic risk to humans-Schistosomes, liver flukes, and Helicobacter pylori. Lyon, France 1994. p. 177–240.
8. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO: classification of tumors of the digestive system. 4th ed. Geneva: IARC Press; 2010.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008;127(12):2893–917.
10. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane database of systematic reviews (Online). 2006(2):CD003840.
11. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane database of systematic reviews (Online). 2003(4):CD004062.
12. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15(12):1949–58.
13. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97(18):1345–53.
14. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20(6):1086–93.
15. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342(8871):575–7.
16. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187–94.
17. Tulassay Z, Stolte M, Engstrand L, Butruk E, Malfertheiner P, Dite P, et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol. 2010;45(9):1048–58.
18. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275–8. doi:10.1111/j.1523-5378.2007.00518.x.
19. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: is the end coming? World J Gastrointest Pharmacol Ther. 2015;6(4):183–98. doi:10.4292/wjgpt.v6.i4.183. Provides a helpful overview of worldwide antibiotic resistance patterns.
20. Teyssen S, Chari ST, Scheid J, Singer MV. Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. Dig Dis Sci. 1995;40(2):247–55.
21. Code CF. Defense mechanisms of the gastric mucosa. Scand J Gastroenterol Suppl. 1981;67:201–4.
22. Henriksnas J, Phillipson M, Storm M, Engstrand L, Soleimani M, Holm L. Impaired mucus-bicarbonate barrier in Helicobacter pylori-infected mice. Am J Physiol. 2006;291(3):G396–403.
23. Baumgartner HK, Montrose MH. Regulated alkali secretion acts in tandem with unstirred layers to regulate mouse gastric surface pH. Gastroenterology. 2004;126(3):774–83.
24. Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci U S A. 2007;104(17):7235–40.
25. Larkin CJ, Watson RGP, Sloan JM, Stevenson M, Ardill JE, Buchanan D. Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol. 2000;35(6):578–82.
26. Lee A, Dixon MF, Danon SJ, Kuipers E, Megraud F, Larsson H, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7(5):461–5.
27. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36(1):12–6.
28. Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K. Expression of UreI is required for intragastric transit and colonization of gerbil gastric mucosa by Helicobacter pylori. Res Microbiol. 2002;153(10):659–66.
29. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology. 1996;111(4):886–900.
30. Marcus EA, Moshfegh AP, Sachs G, Scott DR. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005;187(2):729–38.
31. Ma Z, Gong S, Richard H, Tucker DL, Conway T, Foster JW. GadE (YhiE) activates glutamate decarboxylase-dependent acid resistance in Escherichia coli K-12. Mol Microbiol. 2003;49(5):1309–20.
32. Scott DR, Marcus EA, Weeks DL, Lee A, Melchers K, Sachs G. Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease. Infect Immun. 2000;68(2):470–7.
33. +-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Sci (New York, NY). 2000;287(5452):482–5.
34. Marcus EA, Sachs G, Wen Y, Feng J, Scott DR. Role of the Helicobacter pylori sensor kinase ArsS in protein trafficking and acid acclimation. J Bacteriol. 2012;194(20):5545–51.
35. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36(10):972–9.
36. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.
37. Molina-Infante J, Shiotani A. Practical aspects in choosing a Helicobacter pylori therapy. Gastroenterol Clin N Am. 2015;44(3):519–35. doi:10.1016/j.gtc.2015.05.004. A clearly written and rational guide explaining why different treatment regimens may be appropriate or less ideal for H. pylori infection in specific circumstances.
38. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012;36(7):627–34. doi:10.1111/apt.12014.
39. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14(10):1319–28.
40. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol. 2008;31(8):546–7.
41. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14(5):603–9.
42. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003;17(Suppl B):36B–40B.
43. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147(8):553–62.
44. Lind T, van Zanten VS, Unge P, Spiller R, Bayerdorffer E, O’Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996;1(3):138–44.
45. Malfertheiner P, Megraud F, O’Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection—the Maastricht Consensus report. The European Helicobacter Pylori study group (EHPSG). Eur J Gastroenterol Hepatol. 1997;9(1):1–2.
46. Khalifa MM, Sharaf RR, Aziz RK. Helicobacter pylori: a poor man’s gut pathogen? Gut Pathog. 2010;2(1):2. doi:10.1186/1757-4749-2-2.
47. Malfertheiner P, Megraud F, O’ Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–64.
48. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374–84. doi:10.1136/gut.2003.022111.
49. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother. 2003;51(1):9–11.
50. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139(6):463–9.
51. Goodwin A, Kersulyte D, Sisson G, van Zanten VSJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998;28(2):383–93.
52. Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents. 2002;19(1):1–7.
53. Chey WD, Wong BC. Practice parameters committee of the American College of G. American College of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25. doi:10.1111/j.1572-0241.2007.01393.x.
54. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17(11):1333–43.
55. Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64(11):1715–20. doi:10.1136/gutjnl-2015-309900.
56. Qureshi NN, Gallaher B, Schiller NL. Evolution of amoxicillin resistance of Helicobacter pylori in vitro: characterization of resistance mechanisms. Microb Drug Resist. 2014;20(6):509–16. doi:10.1089/mdr.2014.0019.
57. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343–57. doi:10.1111/j.1365-2036.2007.03386.x.
58. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10):1185–90. doi:10.3109/00365521.2015.1037345.
59. Gisbert JP, Romano M, Gravina AG, Solis-Munoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768–75. doi:10.1111/apt.13128.
60. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18(5):373–7. doi:10.1111/hel.12052.
61. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233–8. doi:10.1111/j.1523-5378.2010.00758.x.
62. Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012;4(3):239–43. doi:10.1039/c2mt00180b.
63. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997;11 Suppl 1:27–33.
64. Thomas F, Bialek B, Hensel R. Medical use of bismuth: the two sides of the coin. Clin Toxicol. 2012;S3(004):1–5. doi:10.4172/2161-0495.
65. Lambert JR, Borromeo J, Eaves ER, Hansky J, Korman MG. Efficacy of different dosage regimens of bismuth in eradicating Campylobacter pylori. Gastroenterology. 1988;94:A248.
66. Marshall BJ, Valenzuela JE, McCallum RW, Dooley CP, Guerrant RL, Cohen H, et al. Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial. Dig Dis Sci. 1993;38(9):1674–80.
67. McNulty CA. Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori. Rev Infect Dis. 1990;12 Suppl 1:S94–8.
68. Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. Helicobacter. 2000;5(3):176–82.
69. Armstrong JA, Wee SH, Goodwin CS, Wilson DH. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro—an ultrastructural study. J Med Microbiol. 1987;24(4):343–50. doi:10.1099/00222615-24-4-343.
70. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 1987;37 Suppl 2:16–30.
71. Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015. doi:10.1111/apt.13346.
72. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy. 1993;13(2 Pt 2):4S–17S.
73. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents. 2007;29(4):389–96. doi:10.1016/j.ijantimicag.2006.11.007.
74. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother. 1995;39(1):107–11.
75. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment—a pilot study. Helicobacter. 2012;17(5):374–81. doi:10.1111/j.1523-5378.2012.00960.x.
76. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33. doi:10.1111/apt.13497. Provides a comprehensive overview of antibiotic resistance mechanisms, how to test for antibiotic resistance, and how to target therapy based on these results.
77. Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46(9):2996–3000.
78. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther. 2003;18(3):347–53.
79. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40(2):171–7. doi:10.1111/apt.12808.
80. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98(3):562–7.
81. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377(9769):905–13. doi:10.1016/S0140-6736(11)60020-2.
82. O’Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003;17(3):415–20.
83. Muller N, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier JC. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016. doi:10.1016/j.clinre.2015.12.012.
84. Heep M, Beck D, Bayerdorffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999;43(6):1497–9.
85. Heep M, Rieger U, Beck D, Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000;44(4):1075–7.
86. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23(4):481–8. doi:10.1111/j.1365-2036.2006.02793.x.
87. Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19(6):455–61. doi:10.1111/hel.12147.
88. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21. doi:10.1111/j.1365-2036.2011.04937.x.
89. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59(11):1465–70. doi:10.1136/gut.2010.215350.
90. Zullo A, Hassan C, Morini S, De Francesco V, Ierardi E, Panella C, et al. Sequential therapy for H. pylori: an ‘aberrant’ therapy ready for general use. Dig Liver Dis. 2004;36(12):852–3. author reply 3.
91. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205–13. doi:10.1016/S0140-6736(12)61579-7.
92. Gisbert JP, Calvet X, O’Connor A, Megraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44(5):313–25. doi:10.1097/MCG.0b013e3181c8a1a3.
93. Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;43(4):470–81. doi:10.1111/apt.13495.
94. Graham DY, Shiotani A. Which therapy for Helicobacter pylori infection? Gastroenterology. 2012;143(1):10–2. doi:10.1053/j.gastro.2012.05.012.
95. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109–18. doi:10.1111/j.1523-5378.2009.00671.x.
96. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, et al. Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol. 2013;47(3):228–32. doi:10.1097/MCG.0b013e31826015b0.
97. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34. doi:10.2147/CEG.S25419.
98. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177–86 e3. doi:10.1016/j.cgh.2013.05.028. Discussion e12-3.
99. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16(2):139–45. doi:10.1111/j.1523-5378.2011.00828.x.
100. Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol. 2015;21(45):12954–62. doi:10.3748/wjg.v21.i45.12954.
101. Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20(2):79–88. doi:10.1111/hel.12180.
102. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20(11):820–3.
103. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis. 2000;19(7):538–41.
104. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136(1):13–24.
105. Graham KS, Malaty H, el-Zimaity HM, Genta RM, Cole RA, al-Assi MT, et al. Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol. 1995;90(9):1415–8.
106. Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol. 1998;33(1):39–43.
107. Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011;31(3):227–38. doi:10.1592/phco.31.3.227.
108. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet. 1998;35(5):391–402.
109. Midolo PD, Turnidge JD, Munckhof WJ. Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent? Antimicrob Agents Chemother. 1996;40(5):1327–8.
110. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895–905 e5. doi:10.1016/j.cgh.2014.10.036. Offers promise for the future of therapy for H. pylori, with an option for decreased antibiotic use, although results are not currently generalizable worldwide.
111. Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015. doi:10.1111/apt.13325.
112. Inaba T, Iwamuro M, Toyokawa T, Okada H. Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy. Aliment Pharmacol Ther. 2016;43(1):179–80. doi:10.1111/apt.13462.
113. Murakami KSY, Shiino M, Funao N, Nishimura A, Asaka M. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori. Gastroenterology. 2014;146 Suppl 5:740.
114. Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann N Y Acad Sci. 1984;429:587–91.
115. Buzas GM. Carbonic anhydrase, acetazolamide and Helicobacter pylori infection. Helicobacter. 2005;10(5):444. doi:10.1111/j.1523-5378.2005.00353.x.
116. Shahidzadeh R, Opekun A, Shiotani A, Graham DY. Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter. 2005;10(2):136–8. doi:10.1111/j.1523-5378.2005.00306.x.